Updated

Updated · CNBC · Jul 8

US Employers Hold GLP-1 Weight-Loss Coverage at 36% as Drug Costs Take 11.4% of Claims

Updated

Updated · CNBC · Jul 8

US Employers Hold GLP-1 Weight-Loss Coverage at 36% as Drug Costs Take 11.4% of Claims

Q: Could a Washington court ruling force all US employers to cover weight-loss drugs?

No. A Washington court ruling would not force all U.S. employers to cover weight-loss drugs. The ruling cited in Washington is tied to Washington state anti-discrimination law, under which obesity can be treated as a disability. It does not create a national rule, and it does not automatically require coverage even in Washington. It mainly means insurers may have to justify blanket exclusions for obesity drugs rather than deny them outright. Its reach is also limited by how U.S. employer coverage works. Many large employers use self-funded health plans governed by the federal ERISA framework, and those plans generally are not subject to state insurance mandates or most state court-driven coverage rules. So even if Washington ultimately requires broader coverage in state-regulated plans, that would not extend to most employer plans nationwide. There is also no federal law currently requiring private employers to cover GLP-1 drugs for obesity. The broader trend remains the opposite: employers are holding the line because of cost. The latest IFEBP survey shows only 36% cover GLP-1s for both diabetes and weight loss, while 60% cover them for diabetes only. Employers say the main barrier is the drugs’ rising cost, which now accounts for a growing share of claims. The Washington case could influence litigation and policy debates elsewhere, especially around disability discrimination. But for now, it is a state-specific development, not a nationwide mandate.

3 articles · Updated · CNBC · Jul 8

Just 36% of U.S. employers cover GLP-1 drugs for both diabetes and weight loss in 2026, unchanged from 2025, while 60% cover them only for diabetes, up from 55% a year earlier.
11.4% of annual claims now come from GLP-1 drugs, up from 6.9% in 2023, pushing health plans to restrict obesity coverage despite rising demand for Eli Lilly and Novo Nordisk treatments.
27% of employers instead steer workers to direct-to-consumer platforms, and 21% encourage use of FSA, HSA or HRA funds rather than broad plan coverage.
74% of plans offer chronic-care management, while 61% provide nutritional counseling and 61% cover bariatric surgery as lower-cost weight-management alternatives.
Only 9% of employers are considering obesity coverage, with broader adoption hinging on real-world proof that GLP-1s cut other costs; Medicare's new 18-month obesity program may provide early evidence.